ライフサイエンスコーパス: beta-synuclein

1 ession in the cortex of mice over-expressing beta-synuclein.

2 e-knockout (KO) mice that lack alpha- and/or beta-synuclein.

3 synuclein is redundant with the very similar beta-synuclein.

4 d in untransfected cells or cells expressing beta-synuclein.

5 calization, in particular between alpha- and beta-synuclein.

6 rogeny of these mice that also express human beta-synuclein, a homologue of alpha-synuclein, show sig

7 The levels of beta-synuclein, a possible negative regulator of alpha-s

8 leins regulate proteasomal function and that beta-synuclein acts as a negative regulator of alpha-syn

9 how sequence differences between alpha- and beta-synuclein affect individual microscopic processes i

10 in cells transfected with vector control or beta-synuclein, alpha-synuclein-transfected cells were r

11 Beta-synuclein also rapidly formed soluble oligomers and

12 In doubly transgenic mice, beta-synuclein ameliorated motor deficits, neurodegenera

13 on might involve direct interactions between beta-synuclein and Akt and suggest that this signaling p

14 In contrast, WT beta-synuclein and all four Tyr-to-Cys mutant beta-synuc

15 synuclein, alpha-synuclein deletion mutants, beta-synuclein and beta/alpha-synuclein chimeras was ass

16 ations that included increased expression of beta-synuclein and gamma synuclein.

17 the contribution of synuclein family members beta-synuclein and gamma-synuclein to DAT trafficking is

18 f two other members of the synuclein family, beta-synuclein and gamma-synuclein, in the development a

19 a-Synuclein has two close homologues, termed beta-synuclein and gamma-synuclein.

20 Here, we find that alpha-synuclein, beta-synuclein, and apolipoprotein A-1 have the conserve

21 Alpha-synuclein and its homologue beta-synuclein are both natively unfolded proteins that

22 alpha and beta-synuclein are homologous proteins found at comparab

23 Our results suggest that the role of beta-synuclein as a putative modulator of neuropathology

24 ifferent cellular environments could control beta-synuclein (betaS) aggregation via altering its char

25 d the LB variant of Alzheimer's disease, but beta-synuclein (betaS) and gamma-synuclein (gammaS) have

26 Further, beta-synuclein (betaS) and gamma-synuclein (gammaS) immu

27 The closely related homolog beta-synuclein (betaS) is essentially fibril-resistant u

28 egenerative pathologies [alpha-synuclein and beta-synuclein (betaS)], as well as in various types of

29 ty and identified as a mixture of alpha- and beta-synucleins by microsequencing and Western blotting.

30 These results suggest that beta-synuclein can act as a natural inhibitor of alpha-s

31 Supporting the hypothesis that beta-synuclein can act as a neurodegeneration-inducing f

32 Recent findings have supported the view that beta-synuclein can act as an ameliorating regulator of a

33 nd efficient aggregation and fibrillation of beta-synuclein can be induced in the presence of a varie

34 Expression of beta-synuclein caused mitochondrial fragmentation, but t

35 mature cultured primary neurons, alpha- and beta-synuclein colocalized almost exclusively with synap

36 PD, we demonstrated that over-expression of beta-synuclein could retard the progression of impaired

37 eta-synuclein and all four Tyr-to-Cys mutant beta-synucleins did not cause protein aggregation and ce

38 mal subunit S6', unlike alpha-synuclein, but beta-synuclein does bind alpha-synuclein and competes wi

39 Unlike alpha-synuclein, overexpressed beta-synuclein does not cause pathological changes in th

40 Unlike its homologue, beta-synuclein does not form fibrils and has been shown

41 ents demonstrated that recombinant monomeric beta-synuclein does not interact with the proteasomal su

42 essentially continuous helix, whereas aS and beta-synuclein encounter a distinct helix break, indicat

43 ence of these metals, mixtures of alpha- and beta-synucleins exhibited rapid fibrillation.

44 ures and showed that the onset of alpha- and beta-synuclein expression was delayed after synaptic dev

45 lein readily assembles into amyloid fibrils, beta-synuclein fails to do so.

46 Furthermore, beta-synuclein formed proteinase K-resistant aggregates

47 We have observed that the beta-synuclein gene (HGMW-approved symbol, SNCB) is high

48 determined the intron-exon structure of the beta-synuclein gene and established sequencing assays th

49 l facilitate the search for mutations in the beta-synuclein gene in patients with Parkinson disease o

50 Although beta-synuclein had no direct effect on proteasomal activ

51 mparable levels in presynaptic terminals but beta-synuclein has a greatly reduced propensity to aggre

52 oxic in transgenic mice, and fibrillation of beta-synuclein has been demonstrated in vitro.

53 Indeed, beta-synuclein has been reported to protect against alph

54 ng body of evidence that alpha-synuclein and beta-synuclein have opposite neuropathophysiological eff

55 beta-Synuclein, however, differs significantly from alph

56 Thus, aberrant accumulation of alpha- and beta-synuclein in degradative organelles are novel featu

57 Others have shown that alpha and beta-synucleins inhibit phospholipase D (PLD), an enzyme

58 Recombinantly expressed alpha- and beta-synucleins inhibit PLD2 activity in vitro (K0.5 10

59 Monomeric alpha- and beta-synucleins inhibited the 20 S and 26 S proteasomal

60 Significantly, beta-synuclein inhibits the generation of A53T alpha-syn

61 No significant incorporation of beta-synuclein into the fibrils was detected.

62 beta-synuclein is closely related to alpha-synuclein and

63 ased on the following observations: 1) human beta-synuclein is highly homologous to alpha-synuclein b

64 The lack of fibrils formed by beta-synuclein is most readily explained by the absence

65 ucing factor, we demonstrated that wild-type beta-synuclein is neurotoxic for cultured primary neuron

66 beta-Synuclein is widely expressed throughout the centra

67 the putative impact of its close homologue, beta-synuclein, is enigmatic.

68 found increased adult neurogenesis in alpha/beta-synuclein knock-out mice.

69 indicated by zinc transporter-3 (ZnT3)-- and beta-synuclein--LI, as well as by Timm staining, all of

70 However, a mutation of beta-synuclein linked to dementia with Lewy bodies rende

71 It has been shown that both alpha- and beta-synucleins may be able to inhibit phospholipase D2

72 Such an anti-amyloidogenic property of beta-synuclein might also provide a novel strategy for t

73 Our results raise the possibility that beta-synuclein might be a natural negative regulator of

74 d with alpha-synuclein accumulation and that beta-synuclein might protect the central nervous system

75 hese results indicate that the mechanisms of beta-synuclein neuroprotection might involve direct inte

76 se B) signaling pathway in the mechanisms of beta-synuclein neuroprotection.

77 uggested that this may be due to the lack in beta-synuclein of a hydrophobic region that spans residu

78 The effects of beta-synuclein on the Akt pathway appear to be by direct

79 ons of these brains, none of which contained beta-synuclein or gamma-synuclein abnormalities.

80 Membrane binding is also strong for beta-synuclein, phosphorylated alpha-synuclein, and a sy

81 The beta-synuclein protein is highly homologous to the alpha

82 ndings indicate that increased expression of beta-synuclein protein results in a reduction of alpha-s

83 rant translocation of presynaptic alpha- and beta-synuclein proteins to these organelles in the perik

84 Beta-synuclein protofibrils do not bind to or permeabili

85 own experiments suggested that antagonism by beta-synuclein resulted from binding to alpha-synuclein

86 ference for the interaction with 2N, whereas beta-synuclein showed preference for 0N.

87 In particular, we show that beta-synuclein strongly suppresses both lipid-induced ag

88 apoE, mitochondrial creatine kinase U-type, beta-synuclein, synaptogyrin-3, synaptophysin, syntaxin

89 )) induce a partially folded conformation of beta-synuclein that triggers rapid fibrillation.

90 We characterized beta-synuclein, the non-amyloidogenic homolog of alpha-s

91 icity in such bigenic mice to the ability of beta-synuclein to reduce alpha-synuclein protein express

92 binding are examined in reference to aS and beta-synuclein to study the sequence characteristics und

93 Beta-synuclein transfection resulted in increased Akt ac

94 We generated beta-synuclein transgenic mice and observed a marked red

95 a-, beta-, and gamma-synuclein revealed that beta-synuclein was eventually as neurotoxic as alpha-syn

96 The metal-induced fibrillation of beta-synuclein was further accelerated by the addition o

97 We found that beta-synuclein was of intermediate toxicity to yeast, an

98 ection with a lentiviral vector encoding for beta-synuclein was protective.

99 beta-Synuclein was the most abundant message (75-80%), f

100 ed in cases of diffuse LBD (DLBD), levels of beta-synuclein were decreased in AD and DLBD, and levels

101 nsgenic mice expressing human (h) alpha- and beta-synuclein were generated.

102 Similarly, cell lines transfected with beta-synuclein were resistant to alpha-synuclein accumul

103 A similar pattern occurs for the homologue, beta-synuclein, which does not undergo pathogenic aggreg

104 beta-Synuclein, which lacks 11 central hydrophobic resid

105 beta-Synuclein, which shares 60% identity with alpha-syn

106 roteasomal activity, co-incubating monomeric beta-synuclein with aggregated alpha-synuclein antagoniz

107 Furthermore, a chimera of beta-synuclein with alpha-synuclein(73-83) inserted was

108 Co-incubating beta-synuclein with gamma-synuclein had no effect on the